Informations générales (source: ClinicalTrials.gov)
Patient's Perspective on the Evolution of Hidradenitis Suppurativa Burden After Secukinumab Initiation: a French Multicentric Prospective Observational Study (SPECTRA)
Observational
Novartis Pharmaceuticals (Voir sur ClinicalTrials)
juin 2024
mars 2027
05 avril 2025
The primary objective of this non-interventional study is to describe the evolution of
Hidradenitis suppurativa (HS) symptoms 12 months after secukinumab initiation based on
the patients' assessment of pain, oozing, and bad smell.
Etablissements
| Les établissements d'Île-de-France dont les données sont issues de ClinicalTrials.gov Origine et niveau de fiabilité des données | |||||
|---|---|---|---|---|---|
| HIA BEGIN | Contact (sur clinicalTrials) | ||||
| Les établissements sans correspondance certaine dans le répertoire FINESS dont les données sont issues de ClinicalTrials.gov Origine et niveau de fiabilité des données | |||||
| Novartis Investigative Site - 06000 - Nice - France | Contact (sur clinicalTrials) | ||||
| Novartis Investigative Site - 12000 - Rodez - France | Contact (sur clinicalTrials) | ||||
| Novartis Investigative Site - 17019 - La Rochelle - France | Contact (sur clinicalTrials) | ||||
| Novartis Investigative Site - 21034 - Dijon - France | Contact (sur clinicalTrials) | ||||
| Novartis Investigative Site - 29609 - Brest - France | Contact (sur clinicalTrials) | ||||
| Novartis Investigative Site - 31400 - Toulouse - France | Contact (sur clinicalTrials) | ||||
| Novartis Investigative Site - 33075 - Bordeaux Cedex - France | Contact (sur clinicalTrials) | ||||
| Novartis Investigative Site - 34295 - Montpellier - France | Contact (sur clinicalTrials) | ||||
| Novartis Investigative Site - 44093 - Nantes Cedex 1 - France | Contact (sur clinicalTrials) | ||||
| Novartis Investigative Site - 56000 - Vannes - France | Contact (sur clinicalTrials) | ||||
| Novartis Investigative Site - 56322 - Lorient - France | Contact (sur clinicalTrials) | ||||
| Novartis Investigative Site - 59037 - Lille - France | Contact (sur clinicalTrials) | ||||
| Novartis Investigative Site - 62100 - Calais - France | Contact (sur clinicalTrials) | ||||
| Novartis Investigative Site - 69003 - Lyon - France | Contact (sur clinicalTrials) | ||||
| Novartis Investigative Site - 72000 - Le Mans - France | Contact (sur clinicalTrials) | ||||
| Novartis Investigative Site - 75014 - Paris - France | Contact (sur clinicalTrials) | ||||
| Novartis Investigative Site - 76031 - Rouen - France | Contact (sur clinicalTrials) | ||||
| Novartis Investigative Site - 92160 - Antony - France | Contact (sur clinicalTrials) | ||||
| Novartis Investigative Site - 97410 - Saint Pierre - France | Contact (sur clinicalTrials) | ||||
Critères
Tous
Inclusion Criteria:
1. Male and female patients ≥ 18 years old,
2. Patients who do not object to participation in the study,
3. Diagnosis of HS clinically confirmed,
4. Initiation of secukinumab treatment for HS in compliance with the summary of product
characteristics,
5. The physician's decision to initiate secukinumab has been taken according to his/her
own practice and regardless of study participation.
1. Male and female patients ≥ 18 years old,
2. Patients who do not object to participation in the study,
3. Diagnosis of HS clinically confirmed,
4. Initiation of secukinumab treatment for HS in compliance with the summary of product
characteristics,
5. The physician's decision to initiate secukinumab has been taken according to his/her
own practice and regardless of study participation.
1. Patients with any medical or psychological condition which, in the physician's
opinion, may prevent participation in the study,
2. Patients participating in a clinical trial.